Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT06178549 Recruiting - Clinical trials for Cervical Cancer Screening

Emergency Room HPV Self-Sampling Study (ACT NOW)

ACT NOW
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to develop and evaluate an evidence-based public health intervention using HPV self-sampling approach in an opportunistic setting to increase cervical cancer screening among screening non-attendees, particularly those uninsured or underinsured, who use emergency services to access medical care. The proposed pilot study will examine the feasibility and efficacy of HPV self-sampling among women at a safety net hospital emergency room. Participant recruitment and self-sample will take place in the waiting rooms in the ER. All women sitting in the waiting room will serve as the source population for the study and will be approached and invited to participate in the study.

NCT ID: NCT06177236 Completed - Cervical Cancer Clinical Trials

Clinic or Self-Sampling for Cervical Cancer Screening

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Objective: The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.

NCT ID: NCT06172478 Recruiting - Prostate Cancer Clinical Trials

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: February 26, 2024
Phase: Phase 2
Study type: Interventional

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.

NCT ID: NCT06169787 Active, not recruiting - Sentinel Lymph Node Clinical Trials

Sentinel Lymph Nodes Biopsy in Cervical Cancer

Start date: October 14, 2023
Phase:
Study type: Observational

This study aims to compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage cervical cancer who underwent radical hysterectomy.

NCT ID: NCT06166420 Recruiting - Cervical Cancer Clinical Trials

Home-based Cervical Cancer Screening Project

CASAHO
Start date: March 27, 2023
Phase: N/A
Study type: Interventional

Cervical cancer is a public health problem in Cameroon.In 2020, the country had a crude incidence of 20.2 per 100 000 women for an incidence to mortality ratio of 0.65. As for now, the country does not have a national screening program to combat the disease. Only 6% of cameroonian women have once been screened for cervical cancer. In order to increase screening uptake so as to reach 70% recommended by the World Health Organization (WHO), a home-based cervical cancer screening approach is proposed. The objective of our study is to compare two recruitment strategies for cervical cancer screening in rural Cameroon.

NCT ID: NCT06165614 Recruiting - Cervix Cancer Clinical Trials

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

To investigate the use of self-administered artesunate vaginal pessaries as treatment for cervical precancer in low and middle-income countries (LMIC). The central hypothesis of this study is that self-administered intravaginal Artesunate will be safe, and result in a clinical response among both HIV-positive and HIV-negative women with cervical precancer in LMICs.

NCT ID: NCT06157151 Recruiting - Cervical Cancer Clinical Trials

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

NCT ID: NCT06156514 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

MICHELE
Start date: November 6, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this phase III clinical trial, is to evaluate the efficacy and safety of concomitant chemo-radiotherapy with Cisplatin vs Gemcitabine as the first line of treatment in patients with locally advanced cervical cancer, with comorbidities and preserved renal function.

NCT ID: NCT06155422 Not yet recruiting - Clinical trials for Recurrent or Metastatic Cervical Cancer

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Start date: November 30, 2023
Phase:
Study type: Observational

This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.

NCT ID: NCT06155396 Recruiting - Cervical Cancer Clinical Trials

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Start date: January 11, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer